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Introduction: In chronic obstructive pulmonary disease (COPD), endothelial dysfunction 
and stiffness of systemic arteries may contribute to increased cardiovascular risk. Pulmonary 
vascular disease (PVD) is frequent in COPD. The association between PVD and systemic 
vascular dysfunction has not been thoroughly evaluated in COPD.
Methods: A total of 108 subjects were allocated into four groups (non-smoking controls, 
smoking controls, COPD without PVD and COPD with PVD). In systemic arteries, endothe-
lial dysfunction was assessed by flow-mediated dilation (FMD) and arterial stiffness by pulse 
wave analysis (PWA) and pulse wave velocity (PWV). PVD was defined by a mean 
pulmonary artery pressure (PAP) ≥25 mmHg at right heart catheterization or by a tricuspid 
regurgitation velocity >2.8 m/s at doppler echocardiography. Biomarkers of inflammation 
and endothelial damage were assessed in peripheral blood.
Results: FMD was lower in COPD patients, with or without PVD, compared to non- 
smoking controls; and in patients with COPD and PVD compared to smoking controls. 
PWV was higher in COPD with PVD patients compared to both non-smoking and smoking 
controls in a model adjusted by age and the Framingham score; PWV was also higher in 
patients with COPD and PVD compared to COPD without PVD patients in the non-adjusted 
analysis. FMD and PWV correlated significantly with forced expiratory volume in the 
first second (FEV1), diffusing capacity for carbon monoxide (DLCO) and systolic PAP. 
FMD and PWV were correlated in all subjects.
Discussion: We conclude that endothelial dysfunction of systemic arteries is common in 
COPD, irrespective if they have PVD or not. COPD patients with PVD show increased 
stiffness and greater impairment of endothelial function in systemic arteries. These findings 
suggest the association of vascular impairment in both pulmonary and systemic territories in 
a subset of COPD patients.
Keywords: COPD, pulmonary circulation and pulmonary hypertension, emphysema, 
cardiovascular diseases
Plain Language Summary
Patients who suffer from an obstruction to the flow of air in their airways (a condition that is 
called chronic obstructive pulmonary disease, or COPD) present with stiffness of the 
peripheral blood vessels and an impairment of normal dilation of the arteries in response 
to changes in systemic arterial pressure, as compared to smokers as well as to healthy 
subjects. Furthermore, patients who suffer from disease of the pulmonary vessels, leading 
to a higher pressure in the pulmonary circulation, also present the increased stiffness and 
reduced dilation of peripheral arteries to a greater degree: this finding may suggest that the 
dysfunction in pulmonary and systemic vascular territories might be associated within this 
patient subgroup. For this reason, the non-invasive evaluation of dilation and stiffness in the 
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peripheral arteries could potentially lead to a suspicion of ele-
vated pressure in the pulmonary circulation of patients with 
COPD, a condition that usually requires an invasive procedure 
for its diagnosis.
Introduction
Chronic obstructive pulmonary disease (COPD) is a chronic 
inflammatory lung disorder with systemic effects that has 
been associated with increased cardiovascular risk.1 Indeed, 
cardiovascular disease is a major cause of death in COPD 
patients, accounting for 25% of the overall mortality.2 
Previous studies have shown that COPD is associated with 
changes in systemic vascular function3,4 and circulating bio-
markers of vascular competence5 thereby suggesting the 
presence of associated peripheral artery disease.6 The sever-
ity of endothelial dysfunction in systemic arteries, as 
assessed by flow-mediated dilation (FMD),7 correlates with 
the severity of airflow obstruction and the extent of emphy-
sema in COPD.3 Furthermore, COPD patients exhibit vascu-
lar stiffness in systemic arteries,8,9 which is correlated with 
the severity of emphysema.10
Pulmonary vascular disease (PVD), a term11 that encom-
passes abnormal pulmonary hemodynamics and changes 
suggestive of pulmonary hypertension12 at echocardiogra-
phy, is a frequent complication of COPD, especially in 
advanced disease stages.13 Pulmonary hypertension is 
a strong and independent prognostic factor for mortality in 
COPD patients14 and the presence of PVD has been asso-
ciated with more frequent exacerbation episodes and greater 
use of healthcare resources.15,16
The relationship between PVD and systemic peripheral 
disease has not been well established. Conceivably, given 
that cigarette smoke exposure is a common risk factor for 
alterations in both vascular territories, patients with PVD 
might be more prone to develop peripheral vascular dis-
ease. In this respect, in a previous study, we showed that 
COPD patients with PVD had reduced FMD compared 
with patients without PVD.17
The association of COPD with markers of vascular 
function in systemic vessels, namely stiffness and endothe-
lial function, has been assessed in separated cohorts. 
Furthermore, the association of PVD and systemic vascu-
lar function in COPD has not been thoroughly evaluated. 
Accordingly, the current study aimed to assess systemic 
endothelial function and arterial compliance in the same 
cohort of patients with COPD, as well as to analyze their 
potential relationship with PVD.
Materials and Methods
Study Population
Sixty-one patients with COPD, with and without PVD, and 
47 control subjects with normal pulmonary function (20 of 
them current smokers) were prospectively evaluated. 
COPD was defined by smoking habit, a compatible clin-
ical history, and evidence of chronic airflow obstruction on 
forced spirometry (post-bronchodilator forced expiratory 
volume in the first second/forced vital capacity ratio, FEV1 
/FVC, <70%).18 Patients were clinically stable at the time 
of the study without exacerbation episodes or oral steroid 
treatment during the previous 4 months. All COPD 
patients were on regular bronchodilator treatment and 
most were also receiving inhaled corticosteroids; PVD 
was considered to be present when at right heart catheter-
ization mean pulmonary artery pressure (mPAP) was 
≥25mmHg, fulfilling the definition of pulmonary hyperten-
sion when the study was initiated,12 or when tricuspid 
regurgitation velocity was >2.8 m/s at Doppler echocar-
diography. Patients with left ventricle ejection fraction 
<50% at echocardiography were excluded. Healthy sub-
jects were allocated into two groups according to their 
smoking status (non-smokers and active smokers).
A complete clinical history, physical examination, 
laboratory tests, electrocardiogram, pulmonary function 
tests and echocardiogram were performed in all subjects. 
In patients with COPD, arterial blood gas analysis was 
additionally performed. The following inflammatory and 
endothelial biomarkers were also analyzed: brain natriure-
tic peptide (BNP), high-sensitivity C reactive protein (hs- 
CRP), fibrinogen, vascular endothelial growth factor 
(VEGF), transforming growth factor-beta (TGF-β), inter-
leukin-6 (IL-6), hepatocyte growth factor (HGF), angio-
poietin-2 (ANG-2), cyclic guanosine monophosphate 
(cGMP), soluble tumor necrosis factor receptor type 
I (sTNF-αRI), soluble intercellular adhesion molecule-1 
(sICAM-1), leptin, adiponectin, and soluble tyrosine 
kinase receptor Axl (sAXL).
The study was approved by the Ethics Committee of 
Hospital Clínic of Barcelona (20095026) and conducted in 
accordance with the Declaration of Helsinki on ethical 
principles for medical research involving human subjects. 
All subjects gave written informed consent before being 
included in the study.
All the measurements of vascular distensibility and 
endothelial function were performed in a quiet, tempera-
ture-controlled room (22±2ºC). Subjects fasted and 
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avoided physical exercise, caffeine, alcohol, drugs and 
stimulants for at least 6 hours and rested supine for 15 
minutes before starting the measurements, maintaining this 
position throughout the measurements. All studies were 
performed at the same time of day (afternoon) with the 
same ultrasound machine and by the same operator. FMD 
testing was performed 15–30 minutes after the completion 
of the arterial stiffness tests.
Vascular Stiffness
Arterial stiffness was assessed according to current 
guidelines.19 Both pulse wave analysis (PWA) and pulse 
wave velocity (PWV) measurements were performed by 
applanation tonometry (SphygmoCor System, AtCor 
Medical, Sydney, Australia). Blood pressure was measured 
twice using an automated, non-invasive oscillometric 
sphygmomanometer.
Pulse wave analysis was obtained on the radial artery of 
the right wrist and measured by specifically trained staff. The 
machine derived an aortic pulse pressure waveform from the 
radial artery wave and calculated the component of pulse 
pressure related to the reflection wave due to the increased 
stiffness of the arterial wall by means of the pressure differ-
ence between the reflection wave peak and the incident wave 
peak, expressed as percentage of the central pulse pressure 
(augmentation index, AI).20 Since the timing of the reflection 
wave is obviously affected by heart rate, the AI was also 
normalized at a standard heart rate of 75 beats per minute 
(AI75),21 in order to avoid the potential bias of different heart 
rates across the study groups.
Pulse wave velocity was measured by specifically 
trained staff. We used the R-wave of a simultaneously 
recorded ECG to identify the onset of the pressure wave, 
and applanation tonometry at the carotid and femoral 
arteries to record the pressure waveform, establishing the 
time delay between the R-wave and the beginning of the 
pulse pressure for each of the two central pulses. This 
distance (in meters) divided by the time delay of the 
pressure waveform (seconds) equaled carotid-femoral 
PWV.22 A measurement was accepted when it was repro-
ducible at least twice with minimal variation. The final 
result was the mean of the measurements performed.
Endothelial Function
Endothelial function was assessed by FMD on the brachial 
artery, according to current guidelines23,24 as previously 
described.17 In brief, a blood pressure cuff was placed around 
the forearm. Brachial artery diameter was measured 
longitudinally 5–10 cm above the elbow by ultrasound, 
using a linear vascular transducer 7.5/5.5 MHz connected 
to an echocardiogram (Sonos 5500, Philips Medical 
Systems), and a three-lead electrocardiography was con-
nected to the ultrasound machine. A 60-second baseline 
period was recorded prior to the cuff inflation. After this, 
the blood pressure cuff was inflated to 250 mmHg for 5 
minutes to achieve total brachial arterial occlusion, and 
then rapidly deflated. Recording recommenced immediately 
after deflation and continued for 2 minutes. The brachial 
artery recovered for 15 minutes, after which another baseline 
scan was recorded for 15 seconds.
All the recorded images were transferred to a computer 
for measurement by the automated edge detection software 
(Brachial artery analyzer, MIA-LLC, IA, USA). The FMD 
response was calculated as the percentage of change from 
baseline to peak diameter of the brachial artery after cuff 
deflation.
Statistical Analysis
Data are expressed as mean ±SD when variable distribu-
tion was normal and as median and percentile 25–75 for 
non-normal distributions. The four groups were compared 
with a non-adjusted analysis using ANOVA with post-hoc 
tests (Tukey for continuous variables and Bonferroni for 
categorical variables). Since comorbidities were not 
equally represented within the four groups, and in order 
to correct for their possible confounding effect over 
endothelial dysfunction and arterial stiffness, a linear 
regression model was created comprising all the condi-
tions and discarding them one by one using Akaike infor-
mation criterion (AICc), in order to find out which 
variables (such as age, systemic arterial hypertension, dia-
betes or Framingham score) had an effect on the overall 
differences of FMD, PWA and PWV between groups and 
should thus be included in the final model for each study 
variable, while maintaining the group category as the 
variable of interest. With the linear model thus created, 
we performed Sidak and Tukey multiple comparison tests 
in order to carry out pairwise comparisons. Correlations 
among variables were analyzed using Pearson’s correlation 
tests. P<0.05 was considered significant in all cases.
Results
Anthropometric, clinical and functional characteristics of 
the subjects are shown in Table 1. In the COPD without 
PVD group, 3 patients were in GOLD 1 stage, 16 patients 
in GOLD 2, 13 patients in GOLD 3 and 14 patients in 
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GOLD 4; in the COPD with PVD group no patient was in 
stage 1, one patient was in GOLD 2, 5 patients in GOLD 3 
and 9 patients in GOLD 4. Fifteen patients overall (one 
patient in the smoking group, 4 patients in the COPD 
without PVD group and 10 in the COPD with PVD 
group) underwent right heart catheterization, while the 
other patients were evaluated by means of echocardiogra-
phy. Fifteen patients with COPD fulfilled the criteria for 
PVD. Age, male gender proportion and the number of 
packs-year were higher in COPD patients. COPD patients 
with PVD had greater airflow obstruction, lower DLCO and 
lower PaO2 than COPD patients without PVD. Systemic 
arterial hypertension and diabetes mellitus were more pre-
valent in COPD patients with PVD.
Endothelial Function of Systemic Arteries
In the non-adjusted analysis, FMD was lower in both COPD 
groups, with and without PVD, as compared with non- 
smoking controls; and lower in the COPD with PVD 
group compared with smoking controls (Table 2, 
Figure 1A). In consideration of the different baseline vessel 
diameters, we formulated the ratio between flow-mediated 
dilation and baseline brachial artery diameter, which is an 
index of endothelial dysfunction independent of vessel 





COPD without PVD 
(n=46)
COPD with PVD 
(n=15)
Age, years 56 ± 8 54 ± 8 62 ± 7 ab 64 ± 6 ab
Male gender, n (%) 12 (44%) 9 (45%) 38 (83%) ab 13 (87%) ab
Smoking status
Current smokers, n (%) 0 (0%) 20 (100%) 14 (30%) 2 (13%)
Ex-smokers, n (%) 9 (33%) 0 (0%) 32 (70%) 13 (87%)
Pack-years smoking 4 ± 8 30 ± 24 62 ± 29 ab 69 ± 29 ab
GOLD stage 1-2-3-4, n NA NA 3–16-13-14 0-1-5-9
FEV1, % ref 107 ± 12 103 ± 10 48 ± 20 
ab 30 ± 10 abc
FVC, % ref 106 ± 11 104 ± 12 84 ± 19 ab 65 ± 13 abc
FEV1/FVC, % 79 ± 5 77 ± 5 43 ± 14 34 ± 9
TLC, % ref 106 ± 8 106 ± 9 116 ± 19 a 113 ± 21
RV, % ref 108 ± 18 110 ± 23 181 ± 57 ab 197 ± 62 ab
DLCO, % ref 92 ± 15 85 ± 9 57 ± 20 
ab 39 ± 12 abc
PaO2, mmHg NA NA 73 ± 9 63 ± 10
c
Systemic arterial hypertension, 
n (%)
5 (19%) 3 (15%) 21 (46%) ab 10 (67%) abc
Dyslipidemia, n (%) 7 (26%) 7 (35%) 14 (30%) 6 (40%)
Diabetes mellitus, n (%) 1 (4%) 0 (0%) 2 (4%) 5 (33%) abc
Framingham score, points 4.9 ± 5.1 7.00 ± 6.0 10.2 ± 5.8 a 12.1 ± 6.8 ab
Systolic pulmonary artery pressure, 
mmHg
27 ± 4 27 ± 3 31 ± 3 43 ± 10 abc
Mean pulmonary artery pressure, 
mmHg *
NA NA 21.2 ± 1.9 29.9 ± 5.9 abc
Cardiac index, L/min/m2 * NA NA 2.24 ± 0.89 2.77 ± 0.47 abc
Pulmonary artery wedge pressure, 
mmHg *
NA NA 8.3 ± 3.1 9.30 ± 4.1
Pulmonary vascular resistance, 
dyn·s·cm−5 *
NA NA 247 ± 40 328 ± 113
Left ventricular ejection fraction, % 64 ± 3 64 ± 3 62 ± 5 60 ± 6
Systolic blood pressure, mmHg 124 ± 18 123 ± 16 130 ± 20 135 ± 19
Notes: Results are expressed in mean±standard deviation. a p<0.05 compared with non-smokers; b p<0.05 compared with smokers; c p<0.05 compared with COPD 
without PVD; * Right heart catheterization was performed in 5 patients of the COPD without PVD group and in 10 patients of the COPD with PVD group. 
Abbreviations: COPD, chronic obstructive pulmonary disease; PVD, pulmonary vascular disease; GOLD, Global Initiative for Chronic Obstructive Lung Disease; FEV1, 
forced expiratory volume in 1st second; FVC, forced vital capacity; TLC, total lung capacity; RV, residual volume; DLCO, diffusing capacity for carbon monoxide; PaO2, partial 
pressure of arterial oxygen; NA, not available.
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diameter; this parameter yielded the same results. None of 
the individual conditions (age, gender, BMI) and comorbid-
ities (systemic arterial hypertension, diabetes, hypercholes-
terolemia, renal disease, chronic ischemic disease, cardiac 
failure, Framingham score) included in the linear regression 
model had an effect on the differences between groups, so 
the adjusted analysis was not performed.
Vascular Stiffness of Systemic Arteries
In the non-adjusted analysis, PWV was higher in both 
COPD groups compared with control subjects (smokers 
and non-smokers). It was also higher in the COPD with 
PVD group compared with the COPD without PVD group 
(p =0.037). In the linear model adjusted for age and the 
Framingham score (selected by the Akaike information 
criterion method), PWV was higher in the COPD with 
PVD group compared to non-smoking and smoking con-
trol subjects (Table 2, Figure 1B). There was also a trend 
towards higher PWV in the COPD with PVD group com-
pared to the COPD without PVD group (p=0.06) in the 
adjusted model. There were no differences in PWV 
between non-smokers and smokers control groups. 





COPD without PVD 
(n = 45)
COPD with PVD 
(n = 15)
Flow-mediated dilation, % change from baseline 
diameter
10.10 (6.15–14.30) 6.60 (4.58–9.50) 5.40 (3.13–7.30) a 2.70 (0.78–4.70) ab
Flow-mediated dilation/Baseline brachial artery 
diameter, %/mm
2.50 (1.48–3.82) 1.34 (0.80–2.04) 1.16 (0.49–1.65) a 0.49 (0.18–1.02) ab
Augmentation index, % 25.0 (19.3–35.3) 33.0 (20.0–43.0) 25.0 (17.3–30.0) 27.0 (17.3–34.0)
Augmentation index 75, % 23.5 (17.0–29.3) 26.0 (20.0–40.0) 27.0 (16.8–31.0) 26.0 (19.5–31.8)
Pulse wave velocity, m/s 8.3 (6.6–9.7) 7.6 (6.6–8.9) 9.8 (8.4–11.8) ab 11.4 (10.4–13.2) abc
Notes: Results are expressed as median (percentile 25-percentile 75). Non-adjusted comparisons: ap<0.05 compared with non-smokers; b p<0.05 compared with smokers; 
c p<0.05 compared with COPD without PVD. 
Abbreviations: COPD, chronic obstructive pulmonary disease; PVD, pulmonary vascular disease.
Figure 1 Results of (A) endothelial function, assessed with flow-mediated dilation, and (B) arterial stiffness, assessed with pulse wave velocity, in non-smoking controls, 
smoking controls, chronic obstructive pulmonary disease (COPD) without pulmonary vascular disease (PVD) [COPD PVD(-)] and COPD with PVD [COPD PVD(+)]. 
Boxplots show median and 25–75 percentiles, whiskers show 5 and 95 percentiles, points show values out of this range. Between-group differences were analyzed with 
unadjusted ANOVA using Tukey as post-hoc test; *p<0.05.
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Measurements of PWA, expressed as AI and AI75, did not 
differ between groups, neither in the non-adjusted nor in 
the adjusted models (Table 2).
Relationship Between Systemic Vascular 
Function and Pulmonary Function
Both FMD and PWV correlated with FEV1, DLCO and 
systolic PAP values (Figure 2); also, the number of pack/ 
years correlated with FMD (r =0.393, p <0.001) and PWV (r 
=0.357, p <0.001). FMD and PWV were inversely correlated 
(r=−0.3; p=0.04). Since the group of non-smoking healthy 
subjects might lead to a correlation bias, we repeated the 
analysis excluding this group. Correlations between lung 
function and sPAP and PWV persisted statistically signifi-
cant, whereas correlations with FMD did not. We tested the 
performance of FMD and PWV in predicting the presence of 
PVD using ROC analysis. Both tests had good diagnostic 
performance in identifying PVD, with areas under the curve 
(AUC) of 0.815 and 0.803, FMD and PWV, respectively 
(Figure S1, supplementary material). A FMD <4.5% had 
a sensitivity of 77% and a specificity of 75% in identifying 
PVD. A PWV >10.4 m/s had a sensitivity of 87%, and 
specificity of 72% in identifying PVD.
Inflammatory and Vascular Markers
The plasma levels of the soluble receptor of tumor necro-
sis factor-alpha (sTNF-αRI) were higher in COPD patients 
with PVD, compared with both non-smoking and smoking 
control groups (Table 3). Fibrinogen was increased in 
COPD patients without PVD, compared with both the non- 
smoking and smoking control groups.
Discussion
The results of the present study show that in patients with 
COPD, the presence of PVD is associated with systemic 
arterial dysfunction, characterized by increased vascular 
stiffness and worse endothelial function in systemic 
arteries. This association is irrespective of the presence 
of cardiovascular risk factors, which are more prevalent 
in COPD patients with PVD.
Systemic arterial stiffness, as assessed by PWV, was 
increased in COPD patients compared with control subjects, 
being patients with COPD and PVD those who presented the 
highest PWV values, in the non-adjusted analysis. 
Nevertheless, since in our cohort COPD patients presented 
more frequently cardiovascular risk factors, we analyzed the 
potential effect of associated comorbidities in an adjusted 
linear regression model. In the adjusted model, differences 
between COPD patients with PVD and both non-smoking 
and smoking controls persisted after adjusting for potential 
confounding factors. Furthermore, there was a trend to 
greater PWV in COPD patients with PVD compared with 
those without PVD. Accordingly, greater systemic arterial 
stiffness in the COPD with PVD group cannot be attributed 
to the effect of existing conditions or comorbidities.
Higher PWV in COPD patients has been previously 
shown,10 but to our knowledge, this is the first time that 
this observation is adjusted for potential confounding 
comorbidities, namely cardiovascular risk factors, and 
related to the presence of PVD. Taken together our current 
findings and previous observations suggest that greater 
systemic arterial stiffness in COPD might be the result of 
increased cardiovascular risk factors in this population. 
However, a subgroup of COPD patients with greater stiff-
ness in systemic arteries might be more prone to develop 
PVD and eventually pulmonary hypertension, potentially 
as a result of greater stiffness also in pulmonary vessels.25
Several studies have previously reported endothelial dys-
function of systemic arteries in COPD patients,3,26 and our 
own group17 has already demonstrated the presence of reduced 
FMD in COPD patients with PVD compared to patients with-
out pulmonary vascular impairment. In the current study, we 
extend these previous observations and demonstrate that 
endothelial dysfunction of systemic arteries in COPD is inde-
pendent of the presence of cardiovascular risk factors and that 
both endothelial dysfunction and arterial stiffness are present in 
the same cohort of patients, being inversely related among 
them. Furthermore, COPD patients with PVD consistently 
show the greatest impairment in systemic vascular function, 
as shown in both unadjusted and adjusted linear models.
The reasons why COPD patients with PVD show greater 
systemic vascular disease are not clear. Airway inflammation 
has been previously linked with reduced vascular nitric oxide 
production,27 which could possibly explain a mechanism for 
endothelial dysfunction. However, the hypothesis of a “spill- 
over” of inflammatory mediators from the lung to the sys-
temic circulation is not supported by the current findings, 
since there were no consistent differences among groups in 
the inflammatory mediators that were tested. Cigarette smok-
ing is a common etiologic factor for both systemic28 and 
pulmonary vascular disease.29 Endothelial dysfunction 
might predispose to greater vascular damage and pulmonary 
vascular remodeling which in turn may lead to pulmonary 
artery stiffness. In fact, the number of pack/years correlated 
with both FMD and PWV in our cohort. Pulmonary artery 
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stiffness has been extensively reported in COPD patients,25,30 
and this finding, as measured by magnetic resonance pulse 
wave velocity, is able to identify pulmonary hypertension in 
COPD and is predictive of major cardiovascular events.31 In 
our study, arterial stiffness was not associated with smoking 
habit in patients without COPD, as no differences were 
observed between control smokers and non-smokers. 
Conceivably, vessel stiffness might be a contributing factor 
for the development of PVD. Similar to what has been shown 
in other forms of pulmonary hypertension,32 factors involved 
in vessel stiffening, such as metalloproteases,33 collagen and 
extra-cellular matrix gene expression and transcription,34,35 
which have been shown in pulmonary arteries of COPD 
patients,36 might contribute to the development of PVD in 
COPD. Arterial stiffness could also be induced as a result of 
greater sympathetic nervous activity, through an increased 
vascular tone enhanced by associated sleep apnea37 or ele-
vated carotid chemoreceptor activity.38 However, this seems 
unlikely in our patients since all of them were clinically 
screened to rule out sleep apnea.
Interestingly, sTNF-αRI was significantly elevated in 
COPD patients with PVD. sTNF-αRI has been shown to 
Figure 2 Correlation between flow-mediated dilation (left column) and pulse wave velocity (right column) with forced expiratory volume during the first second (FEV1), 
diffusing capacity for carbon monoxide (DLCO) and systolic pulmonary artery pressure (PAPs; estimated by doppler echocardiography in patients with tricuspid 
regurgitation and thus a measurable PAPs or measured at right heart catheterization). Patients are grouped as non-smoking controls, smoking controls, chronic obstructive 
pulmonary disease (COPD) without pulmonary vascular disease (PVD) [COPD PVD(-)] and COPD with PVD [COPD PVD(+)].
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be elevated in patients with COPD and systemic 
hypertension,39 or coronary artery disease.40 TNFα was 
also elevated in COPD patients with pulmonary 
hypertension.41
Taken together, the interplay between pulmonary and 
systemic vascular disease in COPD patients could be more 
complex than previously considered, although they share 
physiopathological mechanisms42,43 and similar therapeutic 
strategies.44 It is therefore conceivable that COPD patients, 
through the effect of cigarette smoking, develop endothelial 
dysfunction and that, as the disease progresses, this leads to 
remodeling of both pulmonary and systemic vascular beds 
producing stiffness of the vessel wall. Indeed, endothelial 
damage has recently been suggested as a possible pathoge-
netic mechanism in the development of COPD, alongside 
other more traditionally studied pathophysiological 
pathways.45,46 Our observations could support this hypoth-
esis, although further studies are needed to better define the 
role of endothelial dysfunction in this disease.
Results of the present study indicate that pulmonary 
and systemic vascular impairments are interrelated in 
COPD. These findings concur with the previous observa-
tions of altered markers of vascular competence (defined 
as an imbalance between injury and repair capacity of the 
endothelium) in COPD patients with PVD,5 suggesting 
common pathways in the pathobiology of alterations in 
both vascular territories.
Our study has some limitations. First, even though the 
overall cohort comprises more than one hundred patients, 
when broken down into groups, the sample size might not 
be large enough to discern some differences between 
groups. Second, right heart catheterization was not avail-
able in all subjects. Therefore, we cannot ascertain that 
patients with echocardiographic findings suggestive of 
pulmonary hypertension certainly had it. For this reason, 
we used the term PVD to define this subgroup of subjects. 
The proceedings from the 6th World Symposium on 
Pulmonary Hypertension (Nice 2018) suggested to lower 
the mPAP threshold for the diagnosis of pulmonary 
hypertension;47 however, we chose to follow the 
European guidelines12 that were in effect when the study 
was started. Nevertheless, the recent proposal to lower the 
cut-off mPAP value to define pulmonary hypertension47,48 
and the observation in COPD that mPAP values lower than 
25mmHg are associated with adverse clinical outcomes15 
are in favor that patients we classified as having PVD 
certainly had it. Third, we cannot rule out the possibility 
that some of the patients in the PVD group on the basis of 
echocardiographic findings had left ventricular dysfunc-
tion. We excluded patients with reduced ejection fraction 





COPD without PVD 
(n=46)
COPD with PVD 
(n=15)
hsCRP, mg/dL 0.15 (0.05–0.24) 0.09 (0.05–0.33) 0.40 (0.12–0.87) 0.27 (0.20–0.80)
BNP, pg/mL 13.7 (4.1–23.4) 12.0 (7.6–28.1) 13.5 (7.7–24.9) 21.2 (8.4–40.5)
Fibrinogen, g/L 3.40 (3.00–3.70) 3.30 (2.90–3.78) 3.80 (3.10–5.05)ab 4.00 (3.60–4.50)
Glycemia, mg/dL 92 (85–99) 92 (83–99) 96 (87–109) 112 (94–138)
VEGF, detectable % 12 (44.4) 12 (60) 22 (47.8) 7 (46.7)
VEGF, pg/mL 47.0 (20.8–87.3) 13.3 (8.9–40.1) 9.5 (4.6–39.5) 20.7 (16.8–30.0)
TGF-β, ng/mL 2.31 (1.42–3.43) 2.08 (1.39–5.70) 3.00 (2.06–3.65) 2.18 (1.83–3.29)
IL-6, pg/mL 1.74 (0.96–5.23) 2.55 (0.88–8.00) 1.84 (0.87–3.26) 1.12 (0.54–2.07)
HGF, pg/mL 274 (220–437) 257 (218–365) 336 (309–407) 338 (309–448)
Leptin. ng/mL 11.0 (8.8–16.9) 13.9 (6.6–17.4) 11.5 (8.2–22.5) 16.6 (9.5–20.5)
Angiopoietin-2, 
pg/mL
776 (593–939) 942 (599–1319) 923 (746–1172) 1244 (844–1551)
cGMP, nmol/mL 2.52 (2.02–3.18) 2.19 (1.82–3.00) 2.23 (1.81–3.10) 2.58 (2.20–3.09)
sTNF-αRI, pg/mL 1039 (706–1348) 897 (691–1159) 1050 (878–1359) 1303 (1207–1659) ab
sICAM-1, ng/mL 77.1 (59.0–94.5) 85.8 (67.0–144.8) 96.0 (80.7–190.5) 92.6 (82.8–212.4)
Adiponectin, ng/mL 1046 (795–1494) 1118 (859–1628) 927 (691–1223) 815 (717–996)
sAxl, pg/mL 38.3 (15.8–70.9) 42.4 (20.8–69.3) 38.8 (23.0–57.7) 31.9 (20.3–72.7)
Notes: Results are expressed in median (percentile 25-percentile 75). a p<0.05 compared with non-smokers; b p<0.05 compared with smokers. 
Abbreviations: hsCRP, high sensitivity C-reactive protein; BNP, brain natriuretic peptide; VEGF, vascular endothelial growth factor; TGF-β, transforming growth factor; IL- 
6, Interleukin-6; HGF, hepatocyte growth factor; cGMP, cyclic guanosine monophosphate; sTNF-αRI, soluble receptor of tumor necrosis factor-alpha; sICAM-1, soluble 
intercellular adhesion molecule-1; sAxl, adiponectin, soluble tyrosine kinase receptor Axl. COPD, chronic obstructive pulmonary disease; PVD, pulmonary vascular disease.
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at echocardiography and those with intermediate or high 
probability of heart failure with preserved ejection fraction 
based on clinical criteria.49 Nevertheless, we cannot com-
pletely exclude the latter possibility.
Conclusion
The results of the present study show an association 
between systemic and pulmonary vascular impairment 
that suggests common pathophysiological mechanisms. 
The concurrence of endothelial dysfunction, which might 
be triggered by cigarette smoke products, and vascular 
stiffness appears as a potential common mechanism, not 
fully explained by conventional cardiovascular risk fac-
tors. Our results suggest that exploring factors associated 
with systemic vascular impairment in COPD may also 
shed light on the understanding of the development of 
pulmonary hypertension and contribute to reduce the 
impact of vascular comorbidities in this disease.
Abbreviations
AICc, Akaike information criterion; AI, augmentation 
index; AI75, augmentation index normalized at 75 bpm; 
ANG-2, angiopoietin-2; BNP, brain natriuretic peptide; 
cGMP, cyclic guanosine monophosphate; COPD, chronic 
obstructive pulmonary disease; hs-CRP, high- 
sensitivity C reactive protein; FEV1, post-bronchodilator 
forced expiratory volume in the first second; FMD, flow- 
mediated dilation; FVC, forced vital capacity; HGF, hepa-
tocyte growth factor; IL-6, interleukin-6; PH, pulmonary 
hypertension; PVD, pulmonary vascular disease; PWA, 
pulse wave analysis; PWV, pulse wave velocity; sAXL, 
soluble tyrosine kinase receptor; sICAM-1, soluble inter-
cellular adhesion molecule-1; sTNF-αRI, soluble tumor 
necrosis factor receptor type I; TNFα, tumor necrosis 
factor α; VEGF, vascular endothelial growth factor.
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